e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2008
Sucampo Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33609
|
|
13-3929237 |
|
(State or Other Juris-
diction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
4520 East-West Highway, Suite 300 |
|
20814 |
Bethesda, Maryland
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (301) 961-3400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Item 1.01. |
|
Entry into a Material Definitive Agreement. |
In connection with the appointment of John C. Wright as a member of the registrants Board of
Directors, as described in Item 5.02 below, the registrant entered into an Indemnification
Agreement with Mr. Wright effective February 19, 2008. This Indemnification Agreement, among other
things, provides that the registrant will indemnify Mr. Wright to the fullest extent permitted by
law for claims arising in his capacity as a director of the registrant. The Indemnification
Agreement also establishes the procedures that will apply in the event Mr. Wright makes a claim for
indemnification. The Indemnification Agreement is substantially identical to agreements previously
entered into between the registrant and its other directors.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
On February 19, 2008, the Board of Directors increased the number of directors constituting the
registrants Board of Directors to seven and appointed John C. Wright to the resulting vacancy.
Mr. Wright, age 59, was the chief executive officer of Quadramed Corporation, a software company,
from July 2003 to September 2005. Prior to that, Mr. Wright served as a financial consultant. Mr.
Wright was with Ernst & Young LLP, an international auditing firm, from 1971 until 2000, most
recently as an audit partner focusing on the technology sector. Mr. Wright also serves on the
board of directors of Watson Wyatt Worldwide, a global provider of human capital consulting
services.
The press release issued in connection with the announcement of Mr. Wrights appointment to the
Board of Directors is attached as Exhibit 99.1 to this Current Report on Form 8-K.
|
|
|
Item 5.05. |
|
Amendments to the Registrants Code of Ethics, or Waiver of a Provision of the Code of Ethics. |
On February 19, 2008, the Board of Directors amended and restated the Companys Code of Conduct to
clarify and rationalize the chain of internal reporting and assessment with respect to employee
concerns or complaints regarding accounting or auditing matters or alleged violations of the Code.
The amended and restated Code of Conduct is attached as Exhibit 10.1 to this Current Report on
Form 8-K.
|
|
|
Item 9.01. |
|
Financial Statements and Exhibits. |
|
14.1 |
|
Amended and restated Code of Conduct. |
|
|
99.1 |
|
Press Release issued by the registrant on February 22, 2008
announcing the appointment of John C. Wright to the registrants Board of
Directors. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
SUCAMPO PHARMACEUTICALS, INC.
|
|
Date: February 25, 2008 |
/s/ MARIAM E. MORRIS
|
|
|
Name: |
Mariam E. Morris |
|
|
Title: |
Chief Financial Officer |
|
|
EXHIBIT INDEX
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
14.1 |
|
|
Amended and restated Code of Conduct. |
|
|
|
|
|
99.1 |
|
|
Press Release issued by the registrant on
February 22, 2008 announcing the
appointment of John C. Wright to the
registrants Board of Directors. |
exv14w1
EXHIBIT 14.1
Code of
Conduct
2008
Originally adopted: May 3, 2006
Restated: February 19, 2008
The following policies and procedures constitute the Sucampo Code of Conduct (the Code) which is
applicable to all employees of Sucampo Pharmaceuticals, Inc. and its subsidiaries (collectively,
Sucampo or the Company). It is Sucampos intent that this Code guide each employee in the
pursuit of Sucampos business operations in accordance with applicable laws and in highest regard
for ethical standards.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 1 |
|
|
|
|
|
Introduction |
|
|
3 |
|
Conflicts of Interest |
|
|
3 |
|
Competing Against Sucampo |
|
|
4 |
|
Supplier Affiliations |
|
|
4 |
|
Publicly Traded Securities |
|
|
4 |
|
Closely Held Organizations |
|
|
4 |
|
Someone Close To You Working in the Industry |
|
|
4 |
|
Political and Community Service |
|
|
4 |
|
Confidential Information |
|
|
5 |
|
Privacy of Personal Data |
|
|
5 |
|
Personal Data |
|
|
5 |
|
Employee Privacy |
|
|
6 |
|
Gifts, Entertainment and Gratuities |
|
|
6 |
|
Accuracy and Integrity of Books and Records |
|
|
6 |
|
Concerns Regarding Accounting or Auditing Matters |
|
|
7 |
|
Dealings with Independent Auditors |
|
|
7 |
|
Compliance With Laws and Regulations |
|
|
7 |
|
General |
|
|
7 |
|
Antitrust and Competition Laws |
|
|
8 |
|
Foreign Corrupt Practices Act |
|
|
8 |
|
Food and Drug Laws |
|
|
9 |
|
Truth in Advertising |
|
|
9 |
|
Copyrightable Material |
|
|
9 |
|
Boycotts and Export Controls |
|
|
9 |
|
Software |
|
|
9 |
|
Environmental Laws |
|
|
10 |
|
Safety and Health |
|
|
10 |
|
External Business Relationships |
|
|
10 |
|
Fairness in the Field |
|
|
10 |
|
Disparagement |
|
|
10 |
|
External Communications |
|
|
10 |
|
Supplier Relationships |
|
|
10 |
|
Harassment/Equal Employment Opportunity Laws |
|
|
11 |
|
Use of Company Assets |
|
|
11 |
|
Sucampos Work Environment |
|
|
11 |
|
Personal Conduct |
|
|
11 |
|
Offensive Behavior |
|
|
11 |
|
Violent Behavior and Weapons |
|
|
12 |
|
Drugs and Alcohol |
|
|
12 |
|
Insider Trading and Securities |
|
|
12 |
|
Anti-money Laundering |
|
|
12 |
|
Exceptions to the Code |
|
|
12 |
|
Investigation of Violations |
|
|
12 |
|
Certification |
|
|
13 |
|
Reporting Suspected Violations |
|
|
13 |
|
Dissemination and Amendment |
|
|
14 |
|
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 2 |
Code of Conduct
Introduction
This Code of Conduct addresses issues regarding ethical business standards as well as compliance
with laws and regulations pertaining to Sucampos business operations and products. Sucampo expects
each employee to abide by this Code. Failure to abide by this Code may expose Sucampo, its
management and/or you to criminal or civil liability. Keep in mind that the appearance of
impropriety may be as much of an exposure as actual impropriety. In other words, you may be judged
by what you appear to do as well as what you actually do. Consequently, Sucampo requires you to
avoid any actions that create even the appearance of a violation of law, a violation of this Code
or unethical business activity in general.
Sucampos overall success depends on adherence to this Code as much as to its business and
scientific advances. At no time will any Sucampo business or scientific interest justify a
violation of this Code.
This Code applies to:
|
|
|
All Sucampo Employees World-wide |
|
|
|
|
Third parties acting on behalf of Sucampo |
|
|
|
|
Contractors working for Sucampo |
|
|
|
|
Friends and family members of Sucampo employees who have special knowledge of Sucampo
business dealings through their relationship with the Sucampo employee |
Failure to comply with the standards outlined in this Code will result in disciplinary action
including, but not limited to, reprimands, warnings, probation or suspension without pay,
demotions, reductions in salary, discharge and restitution. Certain violations of this Code may
require the Company to refer the matter to the appropriate governmental or regulatory authorities
for investigation or prosecution. Moreover, any supervisor who directs or approves of any conduct
in violation of this Code, or who has knowledge of such conduct and does not immediately report it,
also will be subject to disciplinary action, up to and including discharge.
In addition to the provisions of this Code, all employees are expected at all times to comply with
all applicable laws, statutes and regulations and to conduct themselves according to the highest
ethical standards.
If you have any questions regarding this Code, please speak with your manager, another manager, or
the Legal Department.
General Provisions
Conflicts of Interest
A conflict of interest may arise if you engage in any activity or advance any personal interests at
the expense of Sucampos interests. You are expected to avoid situations in which you could be, or
appear to be, unduly influenced by factors which may prevent you from acting in the best interests
of Sucampo. You may not personally take advantage of opportunities that are discovered through the
use of Sucampo property, information or your position with Sucampo that would otherwise benefit
Sucampo. Accordingly, you are required to review your specific situation with your manager or the
Audit Committee to assess the nature and extent of any concern and how it can be resolved.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 3 |
Competing Against Sucampo
No employee, officer or director shall perform services as a consultant, employee, officer,
director, advisor or in any other capacity for, or have a financial interest in, a direct
competitor of the Company, other than services performed at the request of the Company and other
than a financial interest representing less than one percent (1%) of the outstanding shares of a
publicly-held company
Supplier Affiliations
No employee, officer or director shall use his or her position with the Company to influence a
transaction with a supplier or customer in which such person has any personal interest, other than
a financial interest representing less than one percent (1%) of the outstanding shares of a
publicly-held company.
Publicly Traded Securities
You should not hold a financial interest in a publicly traded company if the combination of your
job, the amount of your investment, and the particular company in which you invested when viewed
objectively by another person, could appear to influence your actions as a Sucampo employee.
In the case of a supplier, if you are involved in deciding whether Sucampo does business with that
supplier, you shall not have any financial interest greater than one percent (1%) of the
outstanding shares of a publicly held company. These guidelines cannot be avoided by acting
indirectly through another person or organization.
Closely Held Organizations
Investments in closely held organizations (typically, closely held corporations, partnerships or
sole proprietorships) are more likely to cause concern because the ties between closely held
organizations and their investors tend to be more significant and extensive than those between
other organizations and their investors. For example, there are generally relatively few investors
or owners of such companies, giving each a greater stake in its ownership and a higher likelihood
of participating in the companys day-to-day operations.
For these reasons, you shall not make any investment in a closely held organization that is a
competitor, supplier, distributor or organization that re-markets Sucampo products or services.
Exceptions must be specifically pre-approved by the Audit Committee. The Corporate Governance
Committee of the Board of Directors must approve any exception for a Section 16 Officer.
Someone Close To You Working in the Industry
If your spouse, another member of your immediate family, or someone else you are close to works for
Sucampo, or works for or is a competitor or supplier of Sucampo, the closeness of the relationship
might lead you to inadvertently compromise Sucampos interests or create an appearance of a
conflict of interest. An employee of Sucampo should not work in a position in which their manager,
or another manager in the same reporting chain, is either a close relative or someone with whom
they have a consensual relationship. Accordingly, you are required to review your specific
situation with the Audit Committee to assess the nature and extent of any concern and how it can be
resolved.
Political and Community Service
Sucampo encourages you to be active in the civic life of your community. However, such service may,
at times, place you in a situation that poses a conflict of interest with Sucampo. Depending on
your position in Sucampo and whether you stand to gain personally, the situation may require you to
abstain from certain decisions. Regardless of whether you abstain, you should make it clear that
you are a Sucampo employee to avoid any charge of trying to conceal your association with Sucampo.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 4 |
Except as permitted by law, and then only when approved by the Chief Executive Officer, Sucampo
will not make contributions or provide any other form of support to a political party, committee or
candidate.
You will not be paid by Sucampo for time spent running for public office, serving as an elected
official or campaigning for a political candidate, unless required by law. You may, however, take
reasonable time off without pay for such activities, if your Sucampo duties permit the time off and
your manager approves it. You also may use vacation time for political activity. When you
participate in community activities or speak publicly regarding community or political issues, make
sure that you do so as an individual. Do not speak or act on Sucampos behalf unless specifically
authorized to do so by a member of Executive Management. Nothing in this section is intended to
interfere with your right to be involved in the political process on your own time and with your
own resources. You are, however, strictly prohibited from working on personal political activities
during Company time and from using Company assets for such activities at any time.
Confidential Information
Employees, officers and directors must maintain the confidentiality of confidential information
entrusted to them by the Company or other companies, including our suppliers and customers, except
when disclosure is authorized by a supervisor or legally mandated. Unauthorized disclosure of any
confidential information is prohibited. Additionally, employees should take appropriate
precautions to ensure that confidential or sensitive business information, whether it is
proprietary to the Company or another company, is not communicated within the Company except to
employees who have a need to know such information to perform their responsibilities for the
Company.
Third parties may ask you for information concerning the Company. Except when disclosure is
authorized by a supervisor or legally mandated, employees, officers and directors (other than the
Companys authorized spokespersons) must not discuss internal Company matters with, or disseminate
internal Company information to, anyone outside the Company, except as required in the performance
of their Company duties and after an appropriate confidentiality agreement is in place. This
prohibition applies particularly to inquiries concerning the Company from the media, market
professionals (such as securities analysts, institutional investors, investment advisers, brokers
and dealers) and security holders. All responses to inquiries on behalf of the Company must be
made only by the Companys authorized spokespersons. If you receive any inquiries of this nature,
you must decline to comment and refer the inquirer to your supervisor or one of the Companys
authorized spokespersons. The Companys policies with respect to public disclosure of internal
matters are described more fully in the Companys Disclosure Policy, which is available on the
Companys Intranet.
You also must abide by any lawful obligations that you have to your former employer. These
obligations may include restrictions on the use and disclosure of confidential information,
restrictions on the solicitation of former colleagues to work at the Company and non-competition
obligations.
Privacy of Personal Data
Sucampo is committed to following responsible personal data management and protection
practices and complying with all applicable laws concerning the protection of personal data.
Protecting personal data is a cornerstone of Sucampos core values and all Sucampo employees,
contractors and vendors are required to comply with the laws of the jurisdiction in which they
operate and follow Sucampos privacy policies and data protection practices.
Personal Data
Personal data is information about an individual that can be used to identify that individual.
Personal information includes, but is not limited to, an individuals name, address, Social
Security number, telephone and fax number, e-mail address, and drivers license number. In the
course of
its business operations, Sucampo collects, maintains, and uses personal data of employees,
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 5 |
healthcare providers, patients, research subjects, consumers, vendors, and contractors. In all
instances, Sucampo has the responsibility of safeguarding the privacy of personal data.
Employee Privacy
The only personal data, including medical and benefit information, that Sucampo collects or
maintains from its employees is that which is necessary for employment-related business purposes.
Computers, communications equipment, telephones, offices, workspaces, desks, etc., and information
or documents (whether paper or electronic) created or stored on or in them, are the property of
Sucampo. As a result, you should not expect any such items to be private. Except for small items
of a personal nature (such as pictures and memorabilia), personal items, files, voice mail, e-mail,
etc., that you consider private should not be kept in or on Sucampos computers, offices,
workspaces, desks, credenzas or file cabinets. Sucampo has the right, but not the obligation, to
conduct periodic reviews and audits of such information and equipment to ensure that Sucampo assets
are being properly used and that employees are complying with Sucampos policies, procedures and
applicable laws and regulations.
Gifts, Entertainment and Gratuities
The use of Company funds or assets for gifts, gratuities or other favors to employees is
prohibited, except to the extent such gifts are in compliance with applicable law, insignificant in
amount and not given in consideration or expectation of any action by the recipient. The use of
Company funds or assets for gifts, gratuities or other favors to government officials is strictly
prohibited.
Employees, officers and directors must not accept, or permit any member of his or her immediate
family to accept, any gifts, gratuities or other favors from any customer, supplier or other person
doing or seeking to do business with the Company, other than items of insignificant value. Any
gifts that are not of insignificant value should be returned immediately and reported to your
supervisor. If immediate return is not practical, they should be given to the Company for
charitable disposition or such other disposition as the Company, in its sole discretion, believes
appropriate.
Common sense and moderation should prevail in business entertainment engaged in on behalf of the
Company. Employees, officers and directors should provide, or accept, business entertainment to or
from anyone doing business with the Company only if the entertainment is infrequent, modest and
intended to serve legitimate business goals.
Bribes and kickbacks are criminal acts, strictly prohibited by law. In addition, there are special
rules in the healthcare industry regulating gifts and entertainment. For example, the federal
Anti-Kickback Statute makes it a criminal act to offer anything of value with the intent to induce
the purchase of a healthcare product paid for by a government program (such as Medicare and
Medicaid) or in return for recommending the purchase of an item such as a certain drug paid for by
a government program. In order to avoid a violation of this law and to avoid the appearance of
impropriety, you shall not seek, accept, offer, promise or give any payments, fees, loans,
services, gifts, property or any other item of value, from or to any person or firm as a condition
or result of doing business with Sucampo anywhere in the world. In addition, it is Sucampos policy
that any gifts or payments to healthcare professionals comply with the American Medical
Associations guidelines on Gifts to Physicians from Industry (the AMA Guidelines).
Accuracy and Integrity of Books and Records
Employees, officers and directors must honestly and accurately report all business transactions.
You are responsible for the accuracy of your records and reports. Accurate information is
essential to the Companys ability to meet legal and regulatory obligations.
All Company books, records and accounts shall be maintained in accordance with all applicable
regulations and standards and accurately reflect the true nature of the transactions they record.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 6 |
The financial statements of the Company shall conform to generally accepted accounting rules and
the Companys accounting policies. No undisclosed or unrecorded account or fund shall be
established for any purpose. No false or misleading entries shall be made in the Companys books
or records for any reason, and no disbursement of corporate funds or other corporate property shall
be made without adequate supporting documentation.
It is the policy of the Company to provide full, fair, accurate, timely and understandable
disclosure in reports and documents filed with, or submitted to, the Securities and Exchange
Commission and in other public communications.
Concerns Regarding Accounting or Auditing Matters
Employees with concerns regarding questionable accounting or auditing matters or complaints
regarding accounting, internal accounting controls or auditing matters may confidentially, and
anonymously if they wish, submit such concerns or complaints in writing to the Companys Chief
Executive Officer at the Companys corporate headquarters [or may use the toll-free telephone
number (1-800-826-6762). See Reporting and Compliance Procedures. All such concerns and
complaints will be forwarded to the Chairman of the Audit Committee of the Board of Directors,. In
any event, a record of all complaints and concerns received by the Company will be provided to the
Audit Committee each fiscal quarter. Any such concerns or complaints may also be communicated,
confidentially and, if you desire, anonymously, directly to the Chairman of the Audit Committee of
the Board of Directors.
The Companys Chief Executive Officer and the Chairman of the Audit Committee will evaluate the
merits of any concerns or complaints received by it and authorize such follow-up actions, if any,
as it deems necessary or appropriate to address the substance of the concern or complaint.
The Company will not discipline, discriminate against or retaliate against any employee who reports
a complaint or concern, unless it is determined that the employee made the report with knowledge
that it was false.
Dealings with Independent Auditors
No employee, officer or director shall, directly or indirectly, make or cause to be made a
materially false or misleading statement to an accountant in connection with (or omit to state, or
cause another person to omit to state, any material fact necessary in order to make statements
made, in light of the circumstances under which such statements were made, not misleading to, an
accountant in connection with) any audit, review or examination of the Companys financial
statements or the preparation or filing of any document or report with the SEC. No employee,
officer or director shall, directly or indirectly, take any action to coerce, manipulate, mislead
or fraudulently influence any independent public or certified public accountant engaged in the
performance of an audit or review of the Companys financial statements.
Compliance With Laws and Regulations
General
It is Sucampos policy to comply with all laws, rules and regulations. The Company requires that
all employees, officers and directors comply with all laws, rules and regulations applicable to the
Company wherever it does business. You are expected to use good judgment and common sense in
seeking to comply with all applicable laws, rules and regulations and to ask for advice when you
are uncertain about them.
Sucampo is organized and governed primarily by U.S. laws, rules and regulations; however, Sucampo
operates through subsidiaries, branches and other legal entities in countries outside the
U.S. and is subject to the laws, rules and regulations of those countries and jurisdictions as
well.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 7 |
Where there is a conflict between U.S. law and the laws of another country, the issue is to
be resolved by management with the concurrence of Sucampos Legal Department.
All investigations by governmental authorities, other than tax matters, are to be managed by
Sucampos Legal Department. Tax matters are to be managed by the Chief Financial Officer. You are
required to contact Sucampos Legal Department or the Chief Financial Officer as
soon as possible regarding an inquiry from any governmental authorities or from other parties
who have filed, or expressed their intention to file, a lawsuit involving Sucampo.
Antitrust and Competition Laws
The purpose of competition laws (also known as antitrust, monopoly, fair trade or cartel laws)
is to preserve and foster fair and honest competition within a competitive market system.
Under these laws, Sucampo may not enter into agreements with other companies (whether
formal or informal) that unreasonably restrict the functioning of the competitive system.
Examples include agreements or communications between Sucampo and:
|
|
a competitor to charge the same price for a product or to divide or allocate markets or
customers; |
|
|
|
a supplier which limits or controls the suppliers production or prohibits the supplier
from selling to a Sucampo competitor; or |
|
|
|
a distributor which prohibits the distributor from handling competitive products. |
These and other agreements that could limit competition are highly questionable, if not illegal,
and must be reviewed with Sucampos Legal Department. A formal agreement with a competitor need
not exist to violate these laws. A general discussion followed by common action can be enough to
show an implied agreement. In an investigation, every communication, written or oral, is subject to
extreme scrutiny. You must not engage in any communication with a competitor that could result in
price-fixing, bidrigging (including complementary bidding), allocation of customers or markets,
boycotts or production limits to restrain trade.
To ensure that Sucampo complies with these laws, all contracts, arrangements and questionable
situations should be reviewed by Sucampos Legal Department, except for standard contracts and
practices already approved by Sucampos Legal Department (such as standard sales and purchasing
agreements and practices).
Sucampo employees are strictly forbidden from discussing prices, pricing policies, sales terms,
inventory levels, business or marketing plans or any other confidential matters concerning the
Companys business, customers, or competitive activities with an employee or other representative
of a competitor. If a competitor raises any of these issues, no matter how casually, you are
required to:
|
|
stop the conversation immediately; |
|
|
|
explain that it is against Company policy to discuss such matters; and if necessary |
|
|
|
leave the meeting or gathering. |
All incidents of this nature should be promptly reported to the Legal Department.
Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act (the FCPA) applies to U.S. individuals and companies, including
their controlled international subsidiaries.
The FCPA has two basic components: (i) anti-bribery provisions and (ii) accounting and
recordkeeping provisions. Sucampo policy strictly prohibits any officer, director, employee, agent
or stockholder acting on behalf of Sucampo from making any payment or engaging in any transaction
which is prohibited by the FCPA.
The anti-bribery provisions prohibit payment of a bribe to a foreign official. The FCPA defines a
bribe as anything of value given or offered to a foreign official in order to influence an act or
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 8 |
decision to obtain, retain or direct business or to secure any improper advantage. Anything of
value is not limited to cash.
Foreign officials include: (i) a non-U.S. official or non-U.S. political party, party official or
candidate for political office; (ii) an employee of a government-owned company, such as a national
utility company; and (iii) an officer or employee of a public international organization, such as a
United Nations agency.
Food and Drug Laws
All employees shall comply, with all applicable laws and regulations, and all Company policies,
procedures, rules and practices governing the research, development, manufacture, marketing and
promotion and distribution of all of Sucampo products. For further information with regard to
Sucampos policies regarding food and drug laws, please review Sucampos Compliance Guidelines and
Standard Operating Procedures (SOPs).
Truth in Advertising
It is Sucampos policy to avoid any misstatement of fact or misleading impression in any of its
advertising, literature, exhibits or other public statements. All statements made in support of our
products should be true statements that can be supported to the satisfaction of a reasonable
person. In addition, any omission of fact, wrongful emphasis or use of illustrative material that
would tend to mislead a reader, listener or viewer is to be avoided. No claim, comparison or other
statement of fact should be included in a message without having sufficient evidence to support it.
It is the joint responsibility of the representative preparing the message and the person in the
business area responsible for the product or service involved to ensure that all facts are true and
properly supported.
Copyrightable Material
In most cases, the copyrights in employee-generated works of authorship, such as manuals and
computer programs, are automatically owned by Sucampo through operation of law. In other cases,
title to the copyrights is given to Sucampo by contractual provisions. Sucampos policy is to limit
the reproduction or distribution of copyrighted material within Sucampo to only that material for
which the copyright is owned by or appropriately licensed to Sucampo. To ensure that material not
owned by Sucampo is appropriately licensed, Sucampo may request a license from the owner of such
material before permitting the material to be placed into or on any Sucampo owned distribution
channel, including any corporate e-mail system. If there is a question of ownership, you should
consult your manager before you distribute material through any distribution channel.
Boycotts and Export Controls
Sucampos and its non-U.S. subsidiaries ability to sell products and services in certain countries
is restricted by U.S. and other laws and regulations. In addition, Sucampo is prohibited from
participating in boycotts against other countries which are considered friends of the U.S. U.S. law
requires that Sucampo report the receipt of any boycott requests to the U.S. Government. If you
become aware of any such request, or if there is any question as to whether a proposed transaction
may violate these regulations, you should consult with the Legal Department.
Software
Most software products purchased by Sucampo are regulated by some form of licensing agreement which
describes the terms, conditions and allowed uses of the software. Sucampo respects copyright laws
and observes the terms and conditions of all license agreements. You may not install any software
on Sucampo computers or equipment unless Sucampo holds a license agreement for the software. In
addition, you may not install Sucampo licensed software on non-Sucampo computer systems, unless the
terms of Sucampos license agreement allows such usage. You may not download or otherwise copy any
part of a software program for any
reason, including development work, unless Sucampo has obtained the rights to do so. Sucampo IT
must approve the installation and/or use of such software in writing.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 9 |
Environmental Laws
Sucampo and all of its employees are responsible for complying with all applicable environmental
laws, rules and regulations and any policies, procedures, rules and practices promulgated by the
Company.
Safety and Health
Sucampo is committed to providing you with a safe and healthy work environment. Employees are
required to comply with all Company policies, procedures, rules and practices with respect to
safety and health, as well as all applicable occupational health and safety laws and regulations.
External Business Relationships
Fairness in the Field
If you work in a sales or marketing activity, Sucampo expects you to compete vigorously and
effectively, but most of all, fairly. You should not take unfair advantage of anyone through
manipulation, concealment, abuse of privileged information, misrepresentation of material
facts or other unfair-dealing practices.
Disparagement
It is Sucampos policy to sell our products on their merits, not by disparaging competitors or
their products. False or misleading statements and innuendoes are improper. You should not make
comparisons that unfairly cast the competitor in a bad light. In short, in all your business
dealings you should stress the advantages of Sucampo products and be sure that all comparisons are
fair and accurate.
External Communications
Sucampo releases information to the public about its financial performance and its position on
significant issues and strategies through the executive management team. Individual employees may
not communicate any information related to the Companys performance or business activities that
has not yet been made public through an official Sucampo release.
All inquiries from the media, should be directed to the IR Director . In non-U.S. locations, all
communication with the media is to be limited to local senior management or designated public
relations representatives. Regardless of location, any inquiries of a potentially negative nature
should be directed to the IR Director.
All inquiries from security analysts should be directed to the Chief Financial Officer. Inquiries
from
outside attorneys, regulators or government agencies should be directed to Sucampos Legal
Department or, in the case of tax matters, to the Chief Financial Officer.
Supplier Relationships
You must treat all suppliers fairly. It is essential that suppliers competing for Sucampos
business have confidence in the integrity of our selection process. In deciding among competing
suppliers, you should weigh all the facts impartially. Whether or not you are in a position to
influence decisions involving the evaluation or selection of suppliers, you must not exert or
attempt to exert influence to obtain special treatment on behalf of a particular supplier.
Suppliers are to be selected in line with Sucampos sourcing strategy and on the basis of a
suppliers ability to satisfy Sucampos requirements, which include quality, price, continuity of
supply, capacity, reliability and technology. To prevent any perception of unfairness, former
employees will generally not be allowed to act as a supplier or suppliers representative for a
period of one year after such persons employment with Sucampo has ended.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 10 |
Harassment/Equal Employment Opportunity Laws
Sucampo strives to provide all employees with a healthy, safe and productive work environment.
Harassment or discrimination based on race, color, religion, gender, sexual orientation, gender
identity, age, national origin, disability, veterans status or other unlawful factors has no place
at Sucampo or at any Sucampo activity. This includes, but is not limited to, sales calls, trade
shows, off-site meetings, training events, team-building activities, Sucampo social functions and
customer or supplier entertainment activities or events. If you believe you have been the victim
of such conduct at Sucampo, or have witnessed it occurring, you are required to report it as soon
as possible to your manager, another manager, the Human Resources Department or the Legal
Department. All complaints of such conduct will be investigated promptly and dealt with
appropriately. As a Sucampo employee you have a responsibility to participate and cooperate openly
and honestly in any internal investigation of misconduct or wrongdoing. Sucampo will not retaliate
against an employee for reporting such conduct, and you will not be subject to disciplinary action
as long as you have not engaged in any improper activity.
Use of Company Assets
You shall not perform non-Sucampo work or solicit non-Sucampo business on Sucampo premises or while
working on Sucampo time. Also, you are not permitted to use Sucampo equipment, systems, telephones,
materials, resources or proprietary information for any non-Sucampo business, with the exception of
very limited and reasonable use of telephones, computer systems (including e-mail and internet) and
copiers for personal matters. In no case are you allowed to access, store or communicate anything
inappropriate for a professional business environment including, but not limited to, information
items or internet sites of a harassing, discriminatory, illegal or sexually explicit nature or
sites that involve gambling or that otherwise violate Sucampo policy. In addition, downloading of
software for personal use is not permitted. Sucampo must hold a license agreement for any software
installed on a Sucampo PC and the installation and/or use of such software must be approved by
Sucampo Information Technology (IT).
You should protect company assets and their efficient use. Theft, carelessness and waste have a
direct impact on Sucampos profitability and should be prevented. All Sucampo assets should be used
for legitimate business purposes.
Each of us is personally responsible for protecting Sucampo assets entrusted to us and for
protecting Sucampo assets in general. You should be alert to any situations or incidents that could
lead to the loss, misuse or theft of Sucampo assets. You should immediately report all such
situations to your manager or, if you are uncomfortable doing so, through the Hotline or Website as
set forth in the section, Reporting Suspected Violations, below. Managers are responsible for
contacting the Director of Internal Audit as soon as they have knowledge of a loss, misuse or theft
of Sucampo assets.
Sucampos Work Environment
Personal Conduct
Sucampos reputation for maintaining the highest standards of business conduct rests on your
daily actions. Each employee is responsible for acting in the best interests of Sucampo and for
conducting him or herself in accordance with this Code while engaging in any Sucampo activity. This
includes, but is not limited to, sales calls, trade shows, off-site meetings and training events,
team-building activities, Sucampo social functions and customer or supplier entertainment
activities or events.
Offensive Behavior
Offensive language; racial, ethnic or religious slurs; or other remarks, jokes or conduct which
encourage or permit an offensive work environment or diminish the worth of another person are not
acceptable. This is true even if others do not seem to object.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 11 |
Violent Behavior and Weapons
Violent behavior, or the threat of violent behavior, even if made in jest, is not acceptable
conduct. Weapons shall not be in your possession while on Sucampo premises or when engaged in any
activity for Sucampo.
Drugs and Alcohol
The use, possession, manufacture, distribution or sale of drugs or other controlled substances
(except where use is authorized by appropriate medical personnel to treat a bona-fide medical
condition of the person possessing them) or alcohol (except where approved by Executive Management)
is prohibited on Sucampo property. Under no circumstance should you be on Sucampo property, in any
Sucampo work environment or engaged in any activity for Sucampo if you are under the influence of,
or affected by, such drugs, controlled substances or alcohol.
Insider Trading and Securities
Employees, officers and directors who have material non-public information about the Company or
other companies, including our suppliers and customers, as a result of their relationship with the
Company are prohibited by law and Company policy from trading in securities of the Company or such
other companies, as well as from communicating such information to others who might trade on the
basis of that information. To help ensure that you do not engage in prohibited insider trading and
avoid even the appearance of an improper transaction, the Company has adopted an Insider Trading
Policy. This policy governs your right to purchase, sell, pledge or donate any securities of the
Company or any other company that you are familiar with by virtue of your relationship with the
Company. A copy of this policy is available on the Companys Intranet. If you have any questions
about whether you may purchase, sell, pledge or donate a security under this policy, you should
consult with the Chief Financial Officer before making any such purchase, sale, pledge or donation.
Anti-money Laundering
The U.S. anti-money laundering laws prohibit engaging in a financial transaction if the person
knows that the funds involved in the transaction were derived from illegal activities. If you
believe that the other party to a business transaction is engaged in any illegal activity or is
using proceeds derived from an illegal activity, you should obtain approval from the Audit
Committee prior to entering into the transaction.
Exceptions to the Code
While some of the policies contained in this Code must be strictly adhered to and no exceptions can
be allowed, in other cases exceptions may be appropriate. Any employee or officer who believes
that an exception to any of these policies is appropriate in his or her case should first contact
his or her immediate supervisor. If the supervisor agrees that an exception is appropriate, the
approval of the Chief Executive Officer must be obtained. The Chief Executive Officer shall be
responsible for maintaining a record of all requests for exceptions to any of these policies and
the disposition of such requests.
Any executive officer or director who seeks an exception to any of these policies should contact
the Chief Executive Officer. Any waiver of this Code for executive officers or directors or any
change to this Code that applies to executive officers or directors may be made only by the Board
of Directors of the Company and will be disclosed as required by law or stock market regulation.
Investigation of Violations
All reported violations of the Code will be promptly evaluated by the Chairman of the Audit
Committee and the Chief Executive Officer to determine if a formal investigation is required and
will be treated confidentially to the extent practicable. The Audit Committee will participate in
all investigations by Sucampo of violations of this Code, with support from other appropriate
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 12 |
functional areas. You are expected to fully cooperate in an investigation of an alleged violation
of this Code. If the result of the investigation indicates that corrective action is required,
Sucampo will decide what steps it should take to rectify the problem and avoid the likelihood of
its recurrence. Such steps could include, but would not necessarily be limited to, training and
disciplinary action.
Certification
Sucampo may require you to sign a certification form confirming that you have received and read the
Code, understand it and are complying with it. The Company may also require certain supervisory
personnel to complete an annual questionnaire regarding their knowledge of any potential violations
of this Code.
Reporting Suspected Violations
Every employee, officer and director has the responsibility to ask questions, seek guidance, report
suspected violations and express concerns regarding compliance with this Code. Any employee,
officer or director who knows or believes that any other employee or representative of the Company
has engaged or is engaging in Company-related conduct that violates applicable law or this Code
should report such information to his or her supervisor or to the Chief Executive Officer, as
described below. You may report such conduct openly or anonymously without fear of retaliation.
The Company will not discipline, discriminate against or retaliate against any employee who reports
such conduct, unless it is determined that the employee made the report with knowledge that it was
false, or who cooperates in any investigation or inquiry regarding such conduct. Any supervisor
who receives a report of a violation of this Code must immediately inform the Chief Executive
Officer.
You may report violations of this Code, on a confidential or anonymous basis, by contacting the
Companys Chief Executive Officer by fax, mail or e-mail at: Sucampo Pharmaceuticals, Inc., 4520
East West Highway, Suite 300, Bethesda, Maryland 20814, telephone: (301) 961-3400. In addition,
the Company has established a toll-free telephone number (1-800-826-6762)]where you can leave a
recorded message about any violation or suspected violation of this Code (the Hotline) and an
internet site (www.nhsonlinereporting.com, Company ID: SUP) where you can submit information about
any violation or suspected violation of this Code (the Website). While we prefer that you
identify yourself when reporting violations so that we may follow up with you, as necessary, for
additional information, you may leave messages anonymously if you wish.
If the Chief Executive Officer receives information regarding an alleged violation of this Code, he
or she will notify the Chairman of the Audit Committee, and they shall, as appropriate, (a)
evaluate such information, (b) if the alleged violation involves an executive officer or a
director, inform the Board of Directors of the alleged violation, (c) determine whether it is
necessary to conduct an informal inquiry or a formal investigation and, if so, initiate such
inquiry or investigation and (d) report the results of any such inquiry or investigation, together
with a recommendation as to disposition of the matter, to the Chief Executive Officer for action,
or if the alleged violation involves an executive officer or a director, report the results of any
such inquiry or investigation to the Board of Directors or a committee thereof. Employees,
officers and directors are expected to cooperate fully with any inquiry or investigation by the
Company regarding an alleged violation of this Code. Failure to cooperate with any such inquiry or
investigation may result in disciplinary action, up to and including discharge.
The Company shall determine whether violations of this Code have occurred and, if so, shall
determine the disciplinary measures to be taken against any employee who has violated this Code.
In the event that the alleged violation involves an executive officer , the Chief Executive
Officer and the Chairman of the Audit Committee shall determine whether a violation of this Code
has occurred and, if so, shall determine the disciplinary measures to be taken against such
executive officer. In the event that the alleged violation involves a Board director, the Board of
Directors shall determine whether a violation of this Code has occurred and, if so, shall determine
the disciplinary measures to be taken against such director.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 13 |
Dissemination and Amendment
This Code shall be distributed to each new employee, officer and director of the Company upon
commencement of his or her employment or other relationship with the Company and shall also be
distributed annually to each employee, officer and director of the Company, and each employee,
officer and director shall certify that he or she has received, read and understood the Code and
has complied with its terms.
The Company reserves the right to amend, alter or terminate this Code at any time for any reason.
The most current version of this Code can be found on the Companys Intranet.
This document is not an employment contract between the Company and any of its employees, officers
or directors.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 14 |
Code of Conduct Certification
I, do hereby certify that:
|
1. |
|
I have received and carefully read the Code of Conduct of Sucampo Pharmaceuticals,
Inc. |
|
|
2. |
|
I understand the Code of Conduct.
|
|
|
3. |
|
I have complied and will continue to comply with the terms of the Code of Conduct. |
EACH EMPLOYEE, OFFICER AND DIRECTOR IS REQUIRED TO SIGN, DATE, AND RETURN THIS CERTIFICATION TO
HUMAN RESOURCES DEPARTMENT WITHIN TEN (10) DAYS OF ISSUANCE. FAILURE TO DO SO MAY RESULT IN
DISCIPLINARY ACTION.
|
|
|
|
|
|
Sucampo Code of Conduct
|
|
Page 15 |
exv99w1
EXHIBIT 99.1
For Immediate Release
Contact:
P. Curtis Schenck
Director, Investor Relations/Public Relations
Phone: +01-301-961-3400
Fax: +01-301-961-3440
cschenck@sucampo.com
Sucampo Pharmaceuticals Appoints John C. Wright,
Retired Ernst & Young Partner, to Board of Directors
Accounting Industry Veteran Brings More Than 30 Years of
Financial Expertise to Independent Director Role
BETHESDA, Maryland, February 22, 2008 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today
announced that John C. Wright, 59, has been appointed to Sucampo Pharmaceuticals Board of
Directors. Wright was a partner of Ernst & Young, LLP, where he served for nearly 30 years until
his retirement in 2000. He becomes the sixth independent member of Sucampo Pharmaceuticals
seven-member Board. Wright will also serve on the Audit Committee.
Wright began his financial career in 1971 as a staff accountant at Ernst & Young and was promoted
to partner in 1982. He has extensive experience in areas including mergers and acquisitions,
domestic and international tax and finance, securities and regulatory affairs.
Following his retirement from Ernst & Young, Wright served as senior vice president and chief
financial officer of Teligent, Inc., a telecommunications company based in McLean, VA, and as chief
financial officer of QuadraMed Corp. (AMEX: QD), a Reston, VA-based provider of information
technology to the healthcare industry, through 2005.
John brings to the Board a depth of financial and capital markets experience that will be
important in helping our company efficiently execute its global expansion of our own product,
AMITIZA®, to Europe and other countries, said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo
Pharmaceuticals chairman and chief executive officer. We are delighted to welcome him to the
Board.
Sucampo is fueled by outstanding science and guided by an experienced, focused management team,
Wright said. I am privileged to join the Board of this dynamic organization and look forward to
furthering the companys success.
In addition to Sucampo Pharmaceuticals, Wright currently serves on the Board of Directors of Watson
Wyatt Worldwide, Inc. (NYSE: WW), a global provider of human capital consulting services.
A native of Asheboro, North Carolina, he received a bachelors degree in accounting from the
University of North Carolina at Chapel Hill.
John C. Wright/2
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses
on the development and commercialization of medicines based on prostones. The therapeutic
potential of prostones, which are bio-lipids that occur naturally in the human body, was first
identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals chairman and chief executive
officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief
executive officer and advisor, international business development.
Sucampo Pharmaceuticals is marketing AMITIZA® (lubiprostone) in the U.S. for chronic
idiopathic constipation in adults and is developing the drug for additional gastrointestinal
disorders with large potential markets. The company expects to begin submitting EU marketing
authorization applications for AMITIZA for chronic idiopathic constipation in the first half of
2008. In addition, the company has a robust pipeline of compounds with the potential to target
underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two
wholly owned subsidiaries: Sucampo Pharma Europe, Ltd. in Oxford, UK with a branch office in Basel,
Switzerland, and Sucampo Pharma, Ltd. in Tokyo and Osaka, Japan. To learn more about Sucampo
Pharmaceuticals and its products, visit www.sucampo.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Sucampo
Pharmaceuticals, Inc. are forward-looking statements made under the provisions of The Private
Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the
words project, believe, anticipate, plan, expect, estimate, intend, should,
would, could, will, may or other similar expressions. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors,
including risks relating to: the results of clinical trials with respect to Sucampo
Pharmaceuticals products under development; the timing and success of submission, acceptance and
approval of regulatory filings; Sucampo Pharmaceuticals dependence on the commercial success of
AMITIZA; Sucampo Pharmaceuticals ability to obtain additional funding required to conduct its
discovery, development and commercialization programs; Sucampo Pharmaceuticals dependence on its
co-marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals
ability to obtain, maintain and enforce patent and other intellectual property protection for its
discoveries. These and other risks are described in greater detail in the Risk Factors section
of Sucampo Pharmaceuticals Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission for the quarter ended September 30, 2007. Any forward-looking statements in this press
release represent Sucampo Pharmaceuticals views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals
anticipates that subsequent events and developments will cause its views to change. However, while
Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point
in the future, it specifically disclaims any obligation to do so, whether as a result of new
information, future events or otherwise.
AMITIZA® is a registered trademark of Sucampo Pharmaceuticals, Inc.
###